ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,084.61
-0.26%
Dow Jones
42,840.26
1.18%
Gold vs US Dollar
2,623.175
0.00%
Brent Oil
72.72
0.00%
Bitcoin
98,607.97
0.87%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ocean Biomedical Inc (OCEA)

  7. Ocean Biomedical Inc (OCEA) News

Ocean Biomedical (OCEA)

Ocean Biomedical Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OCEA
DateTimeSourceHeadlineSymbolCompany
22/11/202421:45GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
22/10/202420:45GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination LetterNASDAQ:OCEAOcean Biomedical Inc
01/10/202412:01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling ResponsesNASDAQ:OCEAOcean Biomedical Inc
27/08/202412:01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention PlatformsNASDAQ:OCEAOcean Biomedical Inc
23/08/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
23/08/202420:30GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
23/07/202421:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
05/06/202411:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024NASDAQ:OCEAOcean Biomedical Inc
30/05/202411:44GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
16/05/202412:01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe DiseaseNASDAQ:OCEAOcean Biomedical Inc
24/04/202420:51GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KNASDAQ:OCEAOcean Biomedical Inc
28/03/202412:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASLNASDAQ:OCEAOcean Biomedical Inc
08/03/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
04/03/202422:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
29/02/202413:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver MeetingNASDAQ:OCEAOcean Biomedical Inc
13/02/202423:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCEAOcean Biomedical Inc
19/01/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
17/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
05/12/202313:15GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 AntibodyNASDAQ:OCEAOcean Biomedical Inc
29/11/202322:41GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
15/11/202311:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
15/11/202311:20Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:OCEAOcean Biomedical Inc
14/11/202313:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
26/10/202309:30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
26/10/202309:30PR Newswire (US)Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
24/10/202310:30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan KurtisNASDAQ:OCEAOcean Biomedical Inc
17/10/202312:01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
12/10/202321:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
12/10/202312:01PR Newswire (US)Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwideNASDAQ:OCEAOcean Biomedical Inc
12/10/202312:01GlobeNewswire Inc.Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients WorldwideNASDAQ:OCEAOcean Biomedical Inc
 Showing the most relevant articles for your search:NASDAQ:OCEA

Your Recent History

LSE
VAST
Vast Resources
LSE
AAZ
Anglo Asian Mining
LSE
BARC
Barclays
LSE
QBT
Quantum Blockchain Techn...
LSE
PRES
Pressure Technologies
LSE
CAD
Cadogan Energy Solutions
LSE
BP.
Bp
LSE
OPG
Opg Power Ventures
LSE
STX
Shield Therapeutics
LSE
HSP
Hargreaves Services
LSE
HVO
Hvivo
LSE
PRTC
Puretech Health
LSE
THX
Thor Explorations
LSE
SDG
Sanderson Design
LSE
OCN
Ocean Wilsons (holdings)...
LSE
GDWN
Goodwin
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads